George Church joins Nuclera’s Scientific Advisory Board

Cambridge, UK, 31 October 2017: Nuclera Nucleics Ltd., a Cambridge, UK-based enzymatic DNA synthesis company, announces the appointment of George Church, Professor of Harvard and MIT to the Nuclera Scientific Advisory Board.

“Demand for custom DNA is growing exponentially – with applications in manufacturing, medicine, and even information storage”, said George Church. “Nuclera represents fresh approaches, which will improve cost and quality very significantly.”

“George’s experience in helping build successful biotech companies, and his visions for the future of synthetic biology will be invaluable for a young and growing company like Nuclera”, said Jiahao Huang, co-founder of Nuclera. “We are privileged to have him be the founding member of our Scientific Advisory Board, and looking forward to working with George to explore novel applications for our enzyme-based DNA synthesis platform.”

Church is Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT). He also leads Synthetic Biology at the Wyss Institute. He developed the first direct genomic sequencing method, and helped initiate the Human Genome Project in 1984, the Personal Genome Project in 2005, and GP-Write in 2016. He has also helped founded more than 14 biotech companies, such as Editas, Gen9bio, Veritas Genetics and eGenesis.


About Nuclera

Nuclera is a next-generation DNA synthesis company creating tailored solutions for the synthetic biology, industrial enzyme engineering, and pharmaceutical industries. Its proprietary enzyme-mediated DNA synthesis platform will enable the rapid and cost-effective production of highly accurate, ultra-long DNA strands. Nuclera aims to be the key provider of long-length variant DNA and genome libraries for protein, biological pathway, and ultimately genome-scale engineering. For more information on Nuclera visit

Comments are closed.